Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
wQZRAF3bN1kNVb82
